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Abstract
Background—Comparative responsiveness data are needed to inform choices about pain 
outcome measures.
Objectives—To compare responsiveness of pain intensity, pain-related function, and composite 
measures, using data from a randomized trial and observational study.
Research Design—Analysis of responsiveness.
Subjects—A total of 427 adults with persistent back, hip, or knee pain were recruited from 
primary care.
Methods—Participants completed Brief Pain Inventory, Chronic Pain Grade (CPG), Roland 
disability, SF-36 bodily pain, and pain global rating of change measures. We used the global rating 
as the anchor for standardized response mean and receiver operating characteristic curve analyses. 
We used the distribution-based standard error of measurement to estimate minimally important 
change. To assess responsiveness to the trial intervention, we evaluated standardized effect size 
statistics stratified by trial arm.
Results—All measures were responsive to global improvement and all had fair-to-good accuracy 
in discriminating between participants with and without improvement. SF bodily pain was less 
responsive than other measures in several analyses. The 3-item PEG was similarly responsive to 
full Brief Pain Inventory scales. CPG and SF bodily pain were less responsive to the trial 
intervention and did not perform well among participants with hip/knee pain. Agreement between 
anchor and distribution-based methods was modest.
Conclusions—If a brief measure is desired, the 3-item PEG is more responsive than the SF 
bodily pain scale. CPG and SF bodily pain scales may be relatively poor choices for trial outcome 
assessment. Both anchor and distribution-based methods should be considered when determining 
clinically important change.
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Chronic pain research depends on valid patient-reported outcome measures to evaluate 
symptom severity, understand disease prognosis, and assess treatment effectiveness. One 
important aspect of a measure's validity is responsiveness, the ability to detect a meaningful 
change in a clinical state.1 Experts have published recommendations for pain outcome 
measures to be used in clinical trials, but few published studies have compared 
responsiveness across different pain outcomes measures.2,3 Additional data on comparative 
responsiveness of pain measures are needed to inform choices about outcome measures for 
observational and experimental chronic pain research.
The Stepped Care for Affective Disorders and Musculoskeletal Pain (SCAMP) study 
included longitudinal assessment of pain with several measures of pain intensity and pain-
related function. Our objective was to compare responsiveness of pain measures—including 
pain intensity, functional interference, and composite measures—among patients with 
moderate-severe persistent musculoskeletal pain enrolled in the SCAMP randomized clinical 
trial and parallel observational cohort study.
Methods
We used data from SCAMP, which enrolled 500 primary care patients with persistent (≥3 
months) back, hip, or knee pain of at least moderate severity (Brief Pain Inventory severity 
≥5). Participants were recruited from internal medicine clinics affiliated with an academic 
public hospital (n = 300) or Veterans Affairs (VA) hospital (n = 200) in Indianapolis. 
SCAMP enrolled patients in 2 concurrent studies, a randomized trial of combined depression 
medication and pain self-management versus usual care (n = 250) and an observational 
cohort study (n = 250). Inclusion criteria for the trial required PHQ-9 (Patient Health 
Questionnaire)scores of ≥10 (consistent with depression of at least moderate severity), 
whereas criteria for the cohort study required PHQ-9 scores of <8 (consistent with absence 
of clinical depression); eligibility criteria for the 2 studies were otherwise identical. Details 
of SCAMP design and enrollment4 and primary outcomes of the trial5 have been published. 
For these analyses, we included participants with data available at both baseline and 12-
month follow-up (n = 427). We examined responsiveness for randomized trial and 
observational cohort participants separately to allow for comparison of findings in the 2 
study populations, which differed in baseline characteristics and symptom trajectories. The 
SCAMP protocol was approved by the Indiana University institutional review board and 
Roudebush VA Medical Center Research and Development review committee.
Measures Evaluated
We assessed responsiveness of the following pain outcome measures:
• The Brief Pain Inventory (BPI) has been validated as a measure of chronic pain in 
primary care and other clinical populations.6–9 The BPI includes 4 items that assess 
the intensity of pain currently and at its least, worst, and average during the past 
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week (rated from 0, “no pain,” to 10, “pain as bad as you can imagine”). An 
additional 7 items assess pain-related functional interference (rated from 0, “does 
not interfere,” to 10, “interferes completely”). We assessed responsiveness of the 4-
item BPI severity and 7-item BPI interference scales, as well as that of the 2 
following variations: (1) a BPI total score that includes all eleven items, and (2) a 3-
item abbreviated scale that includes 1 intensity item and 2 functional items (PEG; 
average Pain intensity during the past week, pain interference with Enjoyment of 
life, and pain interference with General activity).10 For each scale, the total score is 
the average of all items (range, 0–10; higher scores are worse).
• The Chronic Pain Grade Questionnaire (CPG) has been validated as a measure of 
pain severity in primary care, chronic pain, and general populations.11–14 The CPG 
includes 6 items that rate intensity of current pain, average pain, and worst pain, as 
well as pain interference with activities (all rated from 0 to 10). Items other than 
current pain refer to the past 3 months. We assessed responsiveness of the CPG 
pain intensity scale (the first 3 items) and the CPG disability scale (the 3 
interference items). For each scale, the total score is the average of the individual 
item scores multiplied by 10 (range, 0–100; higher scores are worse).
• The Roland Disability Questionnaire is a pain-specific measure of physical 
disability validated in patients with back and other chronic pain conditions.15,16 It 
includes a checklist of 24 statements about current effects of pain on function. The 
total score is the number of items endorsed (range, 0–24; higher scores are worse).
• The Short Form (SF) Bodily Pain Scale is a validated subscale of the Medical 
Outcomes Study SF-36 questionnaire.17,18 It includes 2 items, one that assesses 
intensity of pain (scale range: 1 “none” to 6 “very severe”) and one that assesses 
how much pain has interfered with work (scale range: 1 “not at all” to 5 
“extremely”) over the past 4 weeks. Responses are transformed into a 0 to 100 
score (lower scores are worse).
Reference Standard Measure
We used a patient-reported retrospective global rating of change as the reference standard for 
change in pain.19 At 12 months, participants were asked, “Overall, since starting the study, 
would you say your pain is worse, about the same, or better?” Those who reported their pain 
was better were asked a second question, “How much better is your pain?” with the 
following response options: a little, somewhat, moderately, a lot, or completely better.
Other Measures
Medical comorbidity was assessed using a checklist of common medical conditions.20 The 
Hopkins Symptom Checklist (SCL)-20 was used to assess depression symptom severity.21,22
Missing items in BPI or Roland measures were prorated if 1 to 2 values were missing. 
Missing items in SF bodily pain or CPG scales were prorated if 1 value was missing. If more 
values were missing, the participant was excluded from analysis of that scale. At baseline, 
the number of participants with at least one missing value was 6 (1.4%) for BPI, 5 (1.2%) 
for CPG, 9 (2.1%) for Roland and 0 for SF bodily pain. At 12 months, the number of 
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participants with at least one missing value was 13 (3.0%) for BPI, 27 (6.3%) for CPG, 17 
(4.0%) for Roland and 8 (1.9%) for SF bodily pain.
Analysis
Experts do not agree on a single preferred approach to responsiveness assessment, but 
recommend combining several approaches, including both anchor-based and distribution-
based methods.1,3,23–25 Retrospective patient-reported global ratings of change are the most 
common anchors used for responsiveness analysis in pain research. We used the 12 month 
global rating of change as the reference standard for calculating standardized response 
means (SRM) and receiver operating characteristic (ROC) curve analyses of responsiveness. 
We used a distribution-based method, the standard error of measurement (SEM), to estimate 
minimal clinically important change for each pain measure. Finally, to assess responsiveness 
of each measure to group differences in the randomized trial, we evaluated standardized 
effect size (SES) statistics stratified by trial arm (intervention and control).
Standardized Response Means
The SRM is an effect size index that is advocated for comparing responsiveness of measures 
because it includes the response variance in the denominator.26 Participants were grouped 
into 3 categories according to their global rating of change at 12 months (worse, same, or 
better). For each measure, we calculated the SRM (12 month mean change score/SD of 
change) stratified by category of change.27 We calculated 95% confidence intervals for the 
SRM with a bootstrapping procedure.28 SRM values are unitless and therefore directly 
comparable between measures. They can be interpreted with Cohen's guidelines for two-
group effect sizes (ie, 0.2 is small, 0.5 is moderate, and 0.8 is large).29,30
Area Under the ROC Curve
Deyo and Centor proposed that assessing responsiveness to change is analogous to assessing 
the discriminatory ability of a diagnostic test; therefore ROC curves can be used to assess a 
measure's ability to accurately “diagnose” the presence or absence of a clinically important 
change.31 ROC curves plot sensitivity on the y-axis against (1 - specificity) on the x-axis for 
a measure compared with a reference standard. We calculated the area under the ROC curve 
(AUC) for each outcome measure using patient-reported improvement on the global rating 
of change as the anchor. We also calculated AUCs for a moderate improvement threshold 
(“moderately,” “a lot,” or “completely better”).3,32 AUC values are interpreted as the 
probability of a measure correctly discriminating between patients who have improved and 
those who have not; the possible range is 0.5 (the same as chance) to 1.0 (perfect 
discrimination).
Standard Error of Measurement
Wyrwich and others developed evidence for the SEM as a distribution-based estimate of the 
minimal clinically important difference.24,33,34 We calculated the SEM for each measure by 
multiplying the baseline standard deviation by the square root of 1 minus the baseline 
internal consistency coefficient (Cronbach's alpha). A change equal to one-SEM has been 
proposed as an estimate of minimal clinically important change, so we categorized 
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participants as follows: those with score improvement ≥ 1 SEM from baseline were 
categorized as better, those with score worsening ≥ 1 SEM as worse, and those with <1 SEM 
change as the same. We then calculated weighted kappa statistics35 to explore the agreement 
between classification as better, the same, or worse by one-SEM criteria compared with 
classification by global rating of change criteria.
Effect Sizes Within the Trial
The ability to detect change associated with an efficacious intervention is a necessary 
characteristic of any measure used in clinical trials.3 Primary results of the SCAMP 
randomized trial showed the intervention was effective in reducing pain and pain-related 
functional limitations.5 To assess measures' responsiveness to the intervention, we evaluated 
effect sizes according to trial arm assignment (intervention or control). We calculated change 
scores (12 months minus baseline) and standardized effect sizes (SES = [intervention group 
change minus control group change]/SD of pooled change scores).36 To assess whether 
measures performed similarly among participants with low back pain and those with knee or 
hip pain, we also stratified this analysis by pain location.
Statistical analyses were performed using SAS version 9.1 (SAS Institute Inc., Cary, NC).
Results
Baseline characteristics of participants in the randomized trial (those with pain and 
depression, n = 205) and observational cohort (those with pain and no depression, n = 222) 
are presented in Table 1. Due to successful randomization, characteristics of participants in 
the intervention and control arms of the trial were equivalent.5 Compared with participants 
in the cohort, those in the trial were younger (mean age, 55.7 vs. 62.2, P < 0.001) and less 
likely to be retired (41.9% vs. 22.9%, P < 0.001). By design, the trial group had more 
depressive symptoms (mean SCL-20 score of 1.9, consistent with moderately severe 
depression) than did the cohort group (mean SCL-20 score 0.7, consistent with mild or no 
depression). On every pain measure, the trial group had worse mean baseline scores than the 
cohort group; this is expected because the presence of comorbid depression is consistently 
associated with worse pain severity.37
According to the pain global rating of change, 103 (24.1%) participants were better at 12 
months, 90 (21.1%) were worse, and 234 (54.8%) were about the same. Rates of 
improvement were higher in the trial group (60, 29.3%) than in the cohort group (43, 
19.4%). Rates of worsening were also slightly higher in the trial group (n = 49, 23.9%) than 
in the cohort group (n = 41, 18.5%).
Standardized Response Means
Table 2 shows SRM values for patients classified as worse, the same, and better at 12 
months according to their global rating of change. Overall, the various measures had similar 
effect sizes within each category of change. Participants with improved pain according to the 
global rating had moderate-to-large improvement in scores, regardless of study group. SRM 
values among those who reported improvement were somewhat lower for the CPG and SF 
bodily pain than for other scales.
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Among observational cohort participants, mean SRM values significantly differed between 
the worse and same groups and between the better and same groups for each measure, 
indicating that measures were able to distinguish between participants who did and did not 
report global change in pain, regardless of the direction of change. Among randomized trial 
participants, SRMs significantly differed between the better and same groups for each 
measure; however, values for those who reported feeling worse did not differ from those of 
participants who reported feeling “about the same” at the end of the trial. Cohort participants 
who reported feeling worse at 12 months had small to moderate worsening in scores; in 
contrast, trial participants who felt worse at 12 months had minimal or no change in scores 
on most measures. We secondarily conducted analyses using 6 month change data; results 
were similar to those at 12 months (not shown).
Area Under The ROC Curve
Table 3 shows the area under the ROC curve (AUC) for each measure, first using any 
improvement on the global rating as the reference standard and second, using moderate 
improvement on the global rating. Overall, AUC values were similar between measures, 
although SF bodily pain and CPG disability had the lowest values. Results within the cohort 
and trial groups were similar and most AUC values were consistent with fair to good 
discriminatory ability (range, 0.65– 0.85). The responsiveness of each measure to the 
presence of any improvement was about as good as its responsiveness to moderate 
improvement.
Standard Error of Measurement
Calculated SEM values did not differ substantially by study group (Table 4). We used the 
SEM, an estimate of minimal clinically important change, to categorize patients as better, 
the same, or worse for each measure. Agreement between classification defined by the one-
SEM criteria and by the global rating of change anchor was generally fair.35 For all 
measures in both study groups, one-SEM criteria classified fewer participants as the same 
and more as better than the global rating did. Both one-SEM and global rating criteria 
classified more trial participants than cohort participants as better. However, one-SEM 
criteria classified fewer trial participants than cohort participants as worse; whereas global 
rating criteria classified more trial than cohort participants as worse.
Effect Sizes Within the Randomized Trial
Measures detected a small-to-moderate intervention group effect, with SES ranging from 
0.41 for the CPG intensity scale to 0.67 for the Roland disability questionnaire (Table 5). 
The CPG intensity and disability scales had the lowest overall responsiveness to intervention 
effect (overall SES 0.41 and 0.43, respectively). Among participants with knee or hip pain, 
responsiveness of SF bodily pain (SES, 0.39), and CPG intensity (SES, 0.32) was relatively 
poor. For the other measures, responsiveness to the intervention was comparable among 
participants with back pain and with knee/hip pain.
Krebs et al. Page 6
Med Care. Author manuscript; available in PMC 2016 May 22.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Discussion
Using data from the SCAMP randomized trial and observational cohort studies, we found 
that multiple pain outcome measures were responsive to change among primary care patients 
with persistent back and lower extremity joint pain. We found similar responsiveness, 
overall, for measures of pain intensity, pain-related function, and composite pain and 
function. One brief composite measure (the PEG) was similarly responsive to longer pain 
intensity and function measures; another (the SF bodily pain scale) had relatively poor 
responsiveness.
Keller et al previously found comparable responsiveness of BPI severity, BPI interference, 
CPG intensity, CPG disability, and SF bodily pain scales in an observational study of 
primary care patients with back pain or arthritis.8 We found that measures of pain intensity 
and measures of pain-related function had similar responsiveness compared with patient-
reported global improvement. However, BPI and CPG intensity measures appeared to be 
more responsive than their corresponding function measures to global worsening. Intensity 
and function measures were similarly responsive to the SCAMP intervention, with small-to-
moderate effect sizes.
Guidelines for assessment of pain recommend measuring both pain intensity and pain-
related function.2 A drawback of using separate scales to measure each domain is the need 
to interpret 2 different numbers; this may complicate decision-making if the intensity and 
functional ratings are discordant. Using composite pain measures rather than separate 
intensity and function scales may simplify pain assessment and data analysis. Our finding 
that PEG and BPI composite measures integrating both domains into a single number 
performed comparably to separate BPI intensity and functional interference measures 
support the validity of this strategy.
Given sufficient validity, brief measures are desirable for their enhanced feasibility in both 
large studies and clinical settings. Our findings demonstrate tradeoffs between brevity and 
validity for the shortest scale we assessed, ie, the 2-item SF bodily pain scale. This scale had 
the lowest internal consistency and was less responsive than other measures according to 
several analyses. In contrast, responsiveness of the 3-item composite PEG scale was similar 
to that of the longer scales, suggesting that it may represent a reasonable compromise 
between feasibility and validity.
Recall window is another factor that may affect responsiveness. The 2 scales with the 
longest recall were the least responsive to intervention effect; CPG scales (3 month recall) 
had the lowest overall responsiveness and SF bodily pain (4 week recall) was the next least 
responsive. Responsiveness was better for measures that assessed current (Roland) or past 
week (BPI and PEG) symptoms.
Except for the SF bodily pain and CPG intensity scales, responsiveness to intervention effect 
did not differ substantially according to pain location (back versus hip/knee). This was true 
for the Roland questionnaire, even though it was originally developed for back pain 
assessment.
Krebs et al. Page 7
Med Care. Author manuscript; available in PMC 2016 May 22.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
We found only fair agreement between the one-SEM-based classification and the 
retrospective anchor-based global rating classification of change. For all measures in both 
study groups, the one-SEM criteria classified more participants as improved and fewer as 
unchanged than the global change rating did. This may have occurred because our global 
change anchor was insensitive to truly minimal changes and picked up more clinically 
relevant moderate changes. In the trial group in particular, participants who reported their 
overall pain was “about the same” actually had small score improvements. Sensitivity of 
global change measures is affected by both measure (eg, response options) and patient (eg, 
pain chronicity) factors38; agreement with one-SEM criteria is likely to be affected by these 
factors as well.
Most of our findings were replicated in the 2 distinct SCAMP study groups, although the 
trial and cohort groups differed in ways that could potentially influence results. First, trial 
participants had moderate-severe depression at baseline and those in the cohort study did 
not. Comorbid depression is known to amplify the symptom intensity and disability 
associated with chronic pain37 and may affect performance of pain measures. Second, half 
of the trial participants were exposed to an intervention, which may alter expectations in a 
way that particularly influences retrospective assessment of pain change, our reference 
standard. These factors likely affected apparent responsiveness to worsening in the trial 
group.
This study has several limitations. First, we lack a true external criterion standard for pain 
change. The reference standards we used, global rating of change classification and receipt 
of an efficacious trial intervention, are both imperfect. For example, global rating of change 
can be affected by “present state bias,” in which the rating of change is overly influenced by 
pain severity at the time of the rating.3 Additionally, retrospective rating questions have not 
been standardized, although differences in question formatting may not substantially affect 
responsiveness results.38 Our second reference standard, receipt of an efficacious trial 
intervention, also lacks true independence from the measures being evaluated because 
patient-reported outcomes were necessary to determine the intervention's efficacy. 
Ultimately, no patient-reported measure can be considered a “gold standard” or truly 
independent of the others. Nonetheless, patient-reported measures are the only valid tools we 
have to assess the inherently subjective phenomenon of pain. To increase confidence in our 
findings, we used combined approaches and looked for consistency in relative 
responsiveness of measures.
A second limitation is the use of multiple comparisons between multiple measures. Findings 
of differences between measures should be interpreted with caution and confirmed in future 
research. Another limitation is a likely ceiling effect for worsening of pain in our study 
population. Participants in SCAMP, especially those in the trial, had moderate-severe 
chronic pain at baseline and limited room for pain to worsen. Overall, change scores among 
those who reported improvement were larger in magnitude than change scores among those 
who reported worsening. Finally, these results are most relevant to the samples we studied. 
They may not be generalizable to other patient populations or pain conditions; in particular, 
findings should not be applied to patients who have communication or cognitive 
impairments or those in nursing home or hospital settings. However, because back pain and 
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joint pain are the 2 most common types of chronic pain and because depression comorbidity 
is prevalent, the primary care populations we studied are particularly important for future 
pain research.
What conclusions can be drawn from our findings? First, all measures discriminated 
between study participants with and without improvement over 12 months, so choice among 
these measures for observational research may be based on criteria other than their relative 
responsiveness. Second, if a brief composite measure is desired to enhance feasibility, the 3-
item PEG may be a more responsive option than the 2-item SF bodily pain scale. Third, 
although all measures detected the trial intervention effect, the CPG and SF bodily pain 
scales were less responsive and therefore may be less desirable as primary clinical trial 
outcome measures. Finally, our findings of modest agreement between one-SEM and global 
rating classifications of change support prior recommendations that researchers should 
consider both anchor and distribution-based methods of determining clinically important 
change in pain outcome measures.
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Table 1
Baseline Characteristics of Study Participants by Study Group Enrollment
Characteristic All Participants (n = 427)
Randomized Trial*
(n = 205)
Observational Cohort*
(n = 222) P†
Age, mean yr (SD) 59.1 (13.0) 55.7 (11.4) 62.2 (13.7) <0.001
Women, n (%) 228 (53.4) 110 (53.7) 118 (53.2) 0.917
Race, n (%)
 White 249 (58.3) 122 (59.5) 127 (57.2) 0.890
 Black 163 (38.2) 76 (37.1) 87 (39.2)
 Other 15 (3.5) 7 (3.4) 8 (3.6)
Employment status, n (%) <0.001
 Employed 99 (23.2) 50 (24.4) 49 (22.1)
 Unemployed or unable to work 188 (44.0) 108 (52.7) 80 (36.0)
 Retired 140 (32.8) 47 (22.9) 93 (41.9)
Mean (SD) no. medical diseases 2.7 (1.4) 2.8 (1.5) 2.6 (1.4) 0.188
Pain location, n (%) 0.135
 Back 235 (55.3) 121 (59.0) 114 (51.8)
 Hip or knee 190 (44.7) 84 (41.0) 106 (48.2)
SCL-20 depression, mean (SD) 1.25 (0.84) 1.88 (0.65) 0.66 (0.50) <0.001
BPI severity, mean (SD) 5.7 (1.8) 6.0 (1.8) 5.3 (1.8) <0.001
BPI interference, mean (SD) 5.8 (2.4) 6.9 (2.1) 4.7 (2.2) <0.001
BPI total, mean (SD) 5.7 (2.0) 6.6 (1.8) 4.9 (1.8) <0.001
PEG, mean (SD) 6.0 (2.2) 6.9 (2.0) 5.2 (2.1) <0.001
CPG intensity, mean (SD) 68.3 (16.7) 71.8 (17.0) 65.0 (15.9) <0.001
CPG disability, mean (SD) 56.8 (29.4) 69.1 (25.2) 45.3 (28.5) <0.001
Roland disability, mean (SD) 14.8 (5.5) 17.3 (4.3) 12.4 (5.4) <0.001
SF bodily pain, mean (SD) 35.3 (18.1) 27.0 (15.3) 42.9 (17.0) <0.001
*
Randomized trial participants had moderate-severe pain and moderate-severe depression; observational cohort participants had moderate-severe 
pain and no clinical depression.
†P values are from χ2 or t tests for comparisons between the randomized trial and observational cohort study groups.
BPI indicates Brief Pain Inventory; CPG, Chronic Pain Grade; SD, standard deviation; SCL-20, Hopkins Symptom Checklist-20; SF, Medical 
Outcomes Study Short Form-36.
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Table 2
Standardized Response Means According to Global Change Category at 12 Month for 
Trial, Observational, and Full Study Groups
Pain Measure Global Change Category
12 mo SRM* (95% CI)
Randomized Trial (n = 205)† Observational Cohort (n = 222) Full Study (n = 427)
BPI severity
 Worse 0.29 (0.00, 0.58) 0.75 (0.43, 1.06) 0.49 (0.28, 0.70)
 Same −0.02 (−0.23, 0.18) 0.08 (−0.08, 0.25) 0.04 (−0.08, 0.17)
 Better −0.99 (−1.25, −0.73) −1.07 (−1.38, −0.76) −1.00 (−1.20, −0.81)
BPI interference
 Worse 0.06 (−0.22, 0.35) 0.43 (0.11, 0.75) 0.24 (0.03, 0.45)
 Same −0.50 (−0.70, −0.30) −0.09 (−0.26, 0.08) −0.24 (−0.37, −0.11)
 Better −1.06 (−1.32, −0.79) −0.69 (−1.00, −0.38) −0.86 (−1.10, −0.66)
BPI total
 Worse 0.15 (−0.13, 0.44) 0.63 (0.31, 0.94) 0.37 (0.16, 0.58)
 Same −0.42 (−0.62, −0.22) −0.04 (−0.21, 0.12) −0.18 (−0.31, −0.05)
 Better −1.15 (−1.41, −0.90) −0.99 (−1.30, −0.68) −1.02 (−1.21, −0.82)
PEG
 Worse −0.05 (−0.33, 0.24) 0.35 (0.04, 0.67) 0.15 (−0.06, 0.36)
 Same −0.49 (−0.69, −0.28) −0.13 (−0.30, 0.04) −0.25 (−0.38, −0.12)
 Better −1.14 (−1.41, −0.88) −0.83 (−1.14, −0.52) −0.99 (−1.19, −0.79)
CPG intensity
 Worse 0.56 (0.28, 0.85) 0.60 (0.28, 0.91) 0.57 (0.37, 0.78)
 Same −0.03 (−0.24, 0.17) 0.07 (−0.10, 0.24) 0.02 (−0.10, 0.15)
 Better −0.73 (−0.99, −0.46) −0.68 (−1.00, −0.36) −0.67 (−0.86, −0.48)
CPG disability
 Worse 0.14 (−0.14, 0.43) 0.37 (0.07, 0.70) 0.27 (0.06, 0.48)
 Same −0.25 (−0.45, −0.05) −0.03 (−0.20, 0.14) −0.12 (−0.25, 0.01)
 Better −0.94 (−1.20, −0.67) −0.57 (−0.89, −0.25) −0.77 (−0.97, −0.57)
Roland disability
 Worse 0.35 (0.06, 0.63) 0.57 (0.25, 0.89) 0.45 (0.24, 0.66)
 Same −0.29 (−0.50, −0.09) −0.03 (−0.20, 0.14) −0.11 (−0.24, 0.02)
 Better −1.09 (−1.35, −0.83) −0.67 (−0.98, −0.36) −0.90 (−1.09, −0.70)
SF bodily pain
 Worse −0.17 (−0.45, 0.12) −0.58 (−0.89, −0.27) −0.36 (−0.57, −0.15)
 Same 0.31 (0.11, 0.52) 0.17 (0.00, 0.34) 0.22 (0.09, 0.35)
 Better 0.76 (0.50, 1.02) 0.67 (0.36, 0.98) 0.72 (0.52, 0.92)
*SRM = 12 month-baseline change score/SD of change score.
†
In the trial group, 49 (23.9%) participants were categorized as worse, 96 (46.8%) as the same, and 60 (29.3%) as better. In the observational 
group, 41 (18.5%) were categorized as worse, 138 (62.2%) as the same, and 43 (19.4%) as better.
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BPI indicates Brief Pain Inventory; CPG, Chronic Pain Grade; SD, standard deviation; SF, Medical Outcomes Study Short Form-36; SRM, 
standardized response mean.
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Table 3
Accuracy of Pain Measures for Detecting Improvement in Randomized Trial and 
Observational Cohort Groups
Accuracy for Detecting any Improvement Accuracy for Detecting Moderate Improvement*
Randomized Trial
AUC (SE)
Observational Cohort
AUC (SE)
Randomized Trial
AUC (SE)
Observational Cohort
AUC (SE)
BPI severity 0.81 (0.036) 0.83 (0.032) 0.85 (0.035) 0.81 (0.038)
BPI interference 0.78 (0.040) 0.70 (0.043) 0.77 (0.046) 0.67 (0.052)
BPI total 0.81 (0.038) 0.78 (0.036) 0.81 (0.042) 0.76 (0.044)
PEG 0.78 (0.038) 0.73 (0.040) 0.79 (0.042) 0.70 (0.050)
CPG intensity 0.78 (0.039) 0.75 (0.043) 0.82 (0.040) 0.73 (0.055)
CPG disability 0.75 (0.040) 0.65 (0.044) 0.76 (0.043) 0.66 (0.053)
Roland disability 0.81 (0.037) 0.70 (0.044) 0.85 (0.038) 0.70 (0.050)
SF bodily pain 0.72 (0.044) 0.68 (0.046) 0.77 (0.043) 0.70 (0.054)
AUC is probability of correctly discriminating between patients who have improved and those who have not.
*
Moderate improvement = global rating of “moderately,” “a lot,” or “completely” better.
AUC indicates area under the receiver operating characteristic curve; BPI, brief pain inventory; CPG, chronic pain grade; SF, Medical Outcomes 
Study Short Form-36; SE, standard error.
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